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AbstrACt
Introduction Depression and alcohol use disorders 
are international public health priorities for which there 
is a substantial treatment gap. Brief mental health 
interventions delivered by lay health workers in primary 
care services may reduce this gap. There is limited 
economic evidence assessing the cost-effectiveness of 
such interventions in low-income and middle-income 
countries. This paper describes the proposed economic 
evaluation of a health systems intervention testing the 
effectiveness, cost-effectiveness and cost-utility of two 
task-sharing approaches to integrating services for 
common mental disorders with HIV and diabetes primary 
care services.
Methods and analysis This evaluation will be 
conducted as part of a three-armed cluster randomised 
controlled trial of clinical effectiveness. Trial clinical 
outcome measures will include primary outcomes for 
risk of depression and alcohol use, and secondary 
outcomes for risk of chronic disease (HIV and diabetes) 
treatment failure. The cost-effectiveness analysis will 
evaluate cost per unit change in Alcohol Use Disorder 
Identification Test and Centre for Epidemiological 
Studies scale on Depression scores as well as cost 
per unit change in HIV RNA viral load and haemoglobin 
A1c, producing results of provider and patient cost per 
patient year for each study arm and chronic disease. 
The cost utility analyses will provide results of cost per 
quality-adjusted life year gained. Additional analyses 
relevant for implementation including budget impact 
analyses will be conducted to inform the development of 
a business case for scaling up the country’s investment 
in mental health services.
Ethics and dissemination The Western Cape Department 
of Health (WCDoH) (WC2016_RP6_9), the South African 
Medical Research Council (EC 004-2/2015), the University of 
Cape Town (089/2015) and Oxford University (OxTREC 2–17) 
provided ethical approval for this study. Results dissemination 
will include policy briefs, social media, peer-reviewed papers, 
a policy dialogue workshop and press briefings.
trial registration number PACTR201610001825405.
IntroduCtIon
Common mental disorders (CMDs) including 
depression, anxiety and alcohol use disor-
ders are highly prevalent conditions that 
impose a significant societal cost and impact 
on quality of life.1 Globally, these conditions 
have been shown to be the leading cause of 
non-fatal burden of disease.1 2 The disabling 
impact of these conditions is particularly 
significant in patients suffering from chronic 
physical conditions.3 CMD comorbidity has 
been shown to exacerbate major modifiable 
risk factors for chronic disease; contribute 
to chronic disease progression; increase the 
prevalence of preventable complications and 
strengths and limitations of this study
 ► This study will provide some of the first empirical 
evidence of the cost-effectiveness of integrating 
services for common mental disorders in the prima-
ry care offering for HIV and diabetes.
 ► The study will generate findings that may guide 
priority setting through application of quality-adjust-
ed life year-based outcomes and decision-making 
around the implementation of mental health coun-
selling within the health system.
 ► This paper adds to the growing body of protocols 
for economic evaluations conducted alongside ran-
domised controlled trials.
 ► As health service use is self-reported, there is a pos-
sibility for recall bias, to limit this, a 1-month recall 
period will be used for ambulatory services and a 
6-month recall for hospitalisation, and hospitalisa-
tions will be validated through the Department of 
Health Data Centre.
 ► The 1-year follow-up period may reflect outcomes 
that do not fully represent the full benefit that pa-
tients and the health system could gain through the 
availability of this service; further work using an ex-
tended follow-up period may be proposed.
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disability; result in poor adherence and ultimately lead 
to treatment failure.1 4 There is a plethora of evidence 
on the impact of depression and alcohol use disorders 
on diabetes outcomes.5 6 Likewise, alcohol consumption 
and depressive conditions have been associated with poor 
HIV outcomes.7 8 In addition, high-income country (HIC) 
evidence suggests that patients with these multimorbidi-
ties have higher healthcare costs even after adjusting for 
the costs of mental healthcare9; suggesting potential cost 
savings from investing in mental health treatment for 
patients with multimorbidities.10 
There is a pressing need for evidence on cost-effective 
strategies for integrating mental healthcare into primary 
health services, particularly in low-income and middle-in-
come countries (LMICs), where health systems are typi-
cally fragile and chronically underfunded. In these health 
systems, an investment in mental health services at primary 
care level for patients with chronic disease has the poten-
tial to result in significant returns on investment due to 
reduced chronic disease treatment costs. South Africa—
with the world’s largest ART programme,11 an increasing 
prevalence of diabetes11 and a huge unmet need for CMD 
treatment12—is one LMIC that may benefit from this inte-
grated approach.
Task-sharing13 14 involves redistributing tasks from 
specialist providers to non-specialist health workers,15 
with specialists providing ongoing support to these 
health workers. Task-sharing is a common strategy for 
the provision of primary care services in constrained 
LMIC settings.16 Due to the long lead times in training 
mental health staff and financial resource limitations, 
the task-sharing discourse has found appeal in the policy 
discussions around introducing and expanding mental 
healthcare in LMICs.1 17 These discussions are centred 
on using task-shared approaches18 to upskill lay health 
workers to integrate mental health services such as brief 
counselling interventions into primary care.19 20 Task-
sharing the psychosocial counselling of patients who have 
chronic comorbidities to lay health workers is a particu-
larly appealing and potentially cost-effective strategy to 
treat patients and support their adherence to chronic 
medication21 22 and therefore limit overall health system 
costs of care.4 16
While task-sharing the treatment for CMDs from mental 
health professionals to lower level healthcare workers 
has been suggested as an effective way to deliver services 
within the context of scarce human resources4 and has 
been shown to be cost-effective in some HIC settings, 
there is little if any economic evidence to support the 
implementation of such strategies in LMICs.4 16 This lack 
of evidence limits decision making around the alloca-
tion of resources for these services. Economic evidence 
on the institutional investment, cost-effectiveness and 
budget impact of this approach is necessary for empir-
ically informed health service planning.23 This work 
presents a protocol of a cost-effectiveness (CEA) and 
cost-utility analysis (CUA) from a societal perspective (ie, 
providers and patients) of a task-shared mental health 
counselling intervention for patients with comorbid HIV 
or diabetes in South Africa.
MEthods And AnAlysIs
Patient and public involvement
Patients and the public were engaged with through the 
trial, and were not directly involved in this study.
trial design
This study is nested in Project MIND, a cluster randomised 
controlled trial across 24 public primary care facilities.24 
Myers et al24 describe the trial in detail. The trial will 
compare the effectiveness of treatment as usual (MIND_
TAU) and two alternative methods for integrating a 
psychosocial intervention into the primary care services 
for HIV and diabetes. Treatment as usual (TAU) is repre-
sentative of typical primary care level services for CMD in 
the South African public health service facilities, which 
is typically limited to referrals.25 26 The two models will 
be the dedicated and designated models of care. In the 
dedicated approach (MIND_DED), community health 
workers (CHWs) will be hired and added to the facility 
staff complement and will dedicate their time to only 
delivering the new counselling service. In the designated 
approach (MIND_DES), CHWs already working in the 
facility will be designated to deliver the service in addi-
tion to their other chronic disease-related activities such 
as adherence counselling for HIV and health promotion. 
Supervision and debriefing of all the counsellors in the 
active arms will be task-shifted to registered psycholog-
ical counsellors in line with the national mental health 
policy framework.27 Descriptions of the CHWs and regis-
tered psychological counsellors roles in the MIND-DED 
and MIND-DES models and their qualifications and skills 
levels are detailed in the trial protocol.24
Intervention and comparator
The counselling programme delivered in MIND-DED 
and MIND-DES is based on motivational interviewing 
(MI) and problem solving therapy (PST).28 It is delivered 
in three sessions over 6 weeks with one optional booster 
session. The MI component provides psychoeducation 
about depression and hazardous alcohol use in relation 
to chronic disease, builds readiness for counselling and 
helps participants develop goals for counselling. The 
PST component targets maladaptive coping strategies 
and builds skills and strategies for dealing with life prob-
lems. Patients will receive individual face-to-face coun-
selling from CHWs and take-home booklets to support 
self-learning between sessions. Registered psycholog-
ical counsellors, supervised by psychologists, will train 
the counsellors.24 The underlying theory, content and 
evidence for the efficacy of the counselling approach 
for reducing symptoms of depression and hazardous/
harmful alcohol use over the 1-year time frame have been 
described previously.29–31 In the TAU arm, the standard 
package of care will be provided to patients who are 
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suspected of having mental health problems. In general, 
patients using the HIV or diabetes service are asked by a 
nurse or doctor attending to their care about their mental 
well-being, life stressors and use of alcohol or other 
substances. Patients are provided with advice to change 
their lifestyles. Where the healthcare provider deems it 
necessary, patients are referred to a mental health nurse 
for further assessment or screening. The patient may 
also be referred to a social worker who may refer them 
to non-governmental organisations (NGOs) who provide 
counselling and support services.24
Outcome measures
The primary outcomes for the trial are measures of 
psychosocial functioning, specifically changes in self-re-
ported risk of depression as measured by the Centre for 
Epidemiological Studies scale on Depression (CES-D)32 
and self-reported hazardous alcohol use as measured by 
the Alcohol Use Disorder Identification Test (AUDIT).33 
Secondary outcomes include biological measures aimed at 
assessing changes in chronic disease treatment response, 
specifically haemoglobin A1c (HbA1c) for diabetes and 
HIV-1 RNA viral loads for HIV. Other secondary outcome 
measures include self-reported adherence to chronic 
disease medication and health-related quality of life 
(HRQoL) measured using the EuroQol-5D (EQ-5D).34 
All outcomes are measured longitudinally at baseline, 
and at 6 and 12 months follow-up assessments, recruit-
ment on the trial started in 2017 and will end in February 
2019 and final outcome assessments will end in 2020 
(figure 1).
Sample size and patient population
Recruitment will be restricted to consenting adult 
patients who meet criteria for hazardous alcohol use or 
depression using the AUDIT or CES-D. These patients are 
already diagnosed and receiving treatment for diabetes 
or HIV, but not currently receiving treatment for a CMD. 
The trial requires a sample size of 1200 patients (600 
with HIV and 600 with diabetes) to detect reductions in 
hazardous alcohol use and risk of depression at 12-month 
follow-up. The sample size calculations are based on 
a cluster randomised design with two active arms and 
a control arm. This clinical trial is powered to detect 
clinical outcomes, specifically reductions hazardous/
harmful alcohol use and risk of depression at 12-month 
follow-up rather than economic outcomes.24 35
MInd economic evaluation
Objective
The study will be a prospective economic evaluation. The 
objectives include estimating:
i. Full economic provider costs of the mental health 
intervention; any cost offsets attributable to the in-
tervention related to changes to the costs of HIV or 
diabetes care at the primary care level and changes 
to the costs of referral care (including tuberculo-
sis (TB), emergency department and inpatient care).
ii. Patient costs: associated with the intervention which 
will include direct out-of-pocket payments to private 
health providers (consultations and medications, 
etc), travel and subsistence costs and productivity 
losses.
Figure 1 Economic evaluation: analyses, outcomes, measurement and assessment timing. AUDIT, Alcohol Use Disorder 
Identification Test; BMI, body mass index; CEA, cost-effectiveness analysis; CES-D, Centre for Epidemiological Studies scale 
on Depression; CUA, cost- utility analysis; EQ-5D, EuroQol-5D; HbA1c, haemoglobin A1c; QALY, quality-adjusted life year. 
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iii. Cost-effectiveness in terms of the incremental cost 
per unit of improvement in disease-specific outcome 
(CES-D, AUDIT, HIV-1 RNA, HbA1c).
iv. Cost-utility in terms of the incremental cost per qual-
ity-adjusted life year (QALY) gained.
v. Budget impact of scaling up the intervention.
To achieve these objectives, the incremental cost-effec-
tiveness ratio (ICER) will be calculated by ordering the 
MIND_DED, the MIND_DES and MIND_TAU alterna-
tives from least cost to highest cost and calculating the 
difference in costs and outcomes against the next less 
costly, non-dominated alternative or against the common 
baseline of MIND_TAU.
Perspective
The aim of the economic evaluation is to inform health 
service decision makers about the costs, outcomes, 
economic efficiencies and budget impact of introducing 
task-shared psychosocial counselling to their chronic 
disease patient body in a resource-scarce context. As 
such, the economic evaluation will be conducted from 
a provider perspective, reflecting health service budget 
constraints. In line with good practice recommendations, 
the analyses will also be presented from a societal perspec-
tive (including both provider and patient perspectives). 
While public sector primary healthcare is free at the 
point of use, patients incur time and travel costs when 
accessing care and may experience productivity losses; in 
addition, they may incur costs when using private sector 
health services. These costs will be collected to inform the 
patient perspective within the economic evaluation.
time horizon and discount rate
As the health consequences of the intervention will be 
experienced over a period extending longer than 1 year, 
a discount rate will be applied to reflect differentials in 
timing.36 A 3% discount rate will be used for discounting 
both costs and outcomes to allow comparability with 
other CEAs.37
Estimating intervention effects
Single study-based estimates of clinical effectiveness will 
be obtained from the trial, which will provide the primary 
and secondary outcome measures previously described. 
In addition to the disease-specific primary outcomes, and 
the secondary HIV and diabetes outcomes which will be 
applied in the CEA, the QALY will also be calculated as 
an end point that will be used in the CUA. The ICER 
resulting when using a QALY measure represents the 
additional cost associated with accruing another QALY 
as one compares strategies (ie, the incremental cost per 
QALY gained). The QALY allows comparison of ICERs 
across different diseases and interventions.37 QALYs are 
calculated by multiplying the length of time in a health 
state by the HRQoL of the health state. The EQ-5D is the 
most widely used instrument for measuring HRQoL for 
CUAs.34 In South Africa, it has been validated and trans-
lated into Afrikaans and isiXhosa, two of the country’s 
official languages.38 The EQ-5D is a self-assessment of 
health status across five domains which include mobility, 
self-care, usual activities, pain and discomfort and 
anxiety/depression.39 In this study, the EQ-5D-3L34 will be 
used to measure HRQoL. A single summary index score 
will be generated using preference weights derived from 
a time trade-off (TTO)-based valuation survey conducted 
in Zimbabwe in addition to the commonly used UK value 
set; the TTO is the most common valuation technique 
used in LMICs.40 As the EQ-5D will be administered at 
all the assessment intervals (baseline, 6 months and 
12 months post-enrolment), there will be three observa-
tions of the EQ-5D scores for each patient in the trial. 
The QALY gained per patient over the trial period will 
be calculated by measuring the area under the quality of 
life curve.37
Estimating costs for the provider’s perspective
Within economic evaluation, the appropriate scope of 
provider costs includes all costs incurred within the inter-
vention and any changes in broader health system costs 
that can be attributable to the intervention. We have 
categorised these costs as intervention costs, HIV and 
diabetes service costs and other related provider costs. As 
shown in table 1, our approach to estimating these costs 
entails the measurement of quantities of resources that 
are used, and multiplying these quantities by the value 
(or unit cost) of each resource. These separate steps of 
measurement and valuation are described below.
Measurement of resource use
For the intervention costs, an ingredients approach 
will be used to estimate resources. Routine data linked 
to intervention protocols will be collected and used to 
assess resources directly consumed in the provision of 
the intervention, including supplies, manuals and patient 
education materials. Facility observations of intervention 
delivery will be conducted for the economist to under-
stand the intervention and the facility context; these 
observations will complement intervention cost data 
collection. The costs of intervention focused counsellor 
training and facility-level institutional strengthening and 
capacity development through organisational readiness 
workshops41 will be included in the cost analysis as start-up 
costs42 in order to capture the full economic costs of inte-
grating the intervention into the primary care service for 
patients with chronic disease.42
A time and motion tool (TMT) developed for this evalu-
ation will measure counsellor time usage in delivering the 
intervention for both active arms in the study. Time tools 
have been used in analysis of human resource require-
ments for expanding access to HIV43 and TB care44 using 
lay health workers and have proved useful in highlighting 
the scope of duties of this cadre. To our knowledge, there 
is limited evidence in the South African context on time 
costs of CHW-delivered mental health counselling. The 
TMT will enable an analysis of differences in counsellor 
time usage in the different intervention modalities, 
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Table 1 Measuring and valuing provider costs
Cost component
Measurement Valuation
Resources used
Quantities or 
utilisation Valuation data Allocation factor
Intervention
  Capital costs
   Facility readiness 
workshops
Number of staff Time from trial data Cost of employment 
converted to annual 
equivalent cost
DED/DES/TAU 
headcount
   Intervention training 
for counsellors
Number of counsellors Time from trial data Cost of employment 
converted to annual 
equivalent cost
DED/DES/TAU 
headcount
   Counselling room Space Square metres Replacement value 
converted to annual 
equivalent cost
DED/DES/TAU 
headcount
   Furniture 
and equipment
Tape recorders Inventory Replacement value 
converted to annual 
equivalent cost
DED/DES/TAU 
headcount
   Vehicles Vehicles Inventory Replacement value 
converted to annual 
equivalent cost
DED/DES/TAU 
headcount
  Recurrent costs
   Counselling 
personnel
Number of staff (lay 
counsellors; registered 
counsellors; clinical 
psychologist)
Time from time and 
motion tool
Cost of 
employment×proportion of 
time
DED/DES/TAU 
headcount
   Counselling supplies Manuals, notebooks, pens Number used—from 
trial data
Market value DED/DES/TAU 
headcount
   Non-intervention 
personnel
Number of staff Time from facility 
data
Cost of 
employment×proportion of 
time
Facility headcount
   Utilities Electricity, water, other 
utilities, phone, cleaning, 
transport and stationery
Facility utilisation Annual facility expenditure Facility headcount
HIV/Diabetes service
  Capital costs
   Buildings Space used for HIV/
diabetes service
Square meters Replacement value 
converted to annual 
equivalent cost
HIV/Diabetes 
headcount
   Equipment and 
furniture
Equipment and furniture 
used for HIV/diabetes 
service
Inventory Replacement value 
converted to annual 
equivalent cost
HIV/Diabetes 
headcount
   Vehicles Vehicles used for HIV/
diabetes service
Inventory Replacement value 
converted to annual 
equivalent cost
HIV/Diabetes 
headcount
   Recurrent costs
   HIV/Diabetes 
personnel
Number of staff and staff 
time spent on HIV/diabetes 
service
Time from facility 
data
Cost of employment 
×proportion of time
HIV/Diabetes 
headcount
   Drugs ARV/Diabetes medication Treatment protocol National tender prices Direct allocation
   Diagnostic tests CD4 test, diabetes 
monitoring tests, etc
Treatment protocol National Health Laboratory 
Service prices
Direct allocation
   Non-HIV/diabetes 
personnel
Managerial, cleaning and 
security staff
Facility utilisation Facility expenditure Facility headcount
Continued
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indicating opportunities for scale and scope efficiencies. 
It is anticipated that the costs associated with the TAU 
option will be minimal and any referral costs will be 
captured through patient self-report of services they have 
used.
For the HIV and diabetes services, a step-down method-
ology will be used to establish resource use. Staff time will 
be determined through review of facility organograms 
and interviews with senior managers. In addition, utilisa-
tion of HIV and diabetes medicine and diagnostics will 
be estimated by applying standard treatment guidelines/
protocols for HIV and diabetes treatment in primary 
care services to utilisation statistics obtained from facility 
records (ie, protocol-based facility utilisation statistics)
Establishing the use of referral services is challenging 
given that there is no health information system that 
enables patient pathways through care to be established. 
Therefore, to establish patient utilisation of health services 
beyond their HIV and diabetes care at the primary level, 
we will administer a patient questionnaire developed for 
the study at baseline, and at the 6-month and 12-month 
assessments. Using this questionnaire, we will capture 
health service utilisation for other primary care services 
(eg, TB treatment), hospital services, emergency depart-
ment care, paramedic care and referrals to mental health 
providers. Patients will be asked to quantify the number 
of these additional visits, and lengths of stay in hospital. 
Given concerns with patient recall, we have asked patients 
to estimate their usage of ambulatory services over the 
previous month and have used a recall period of 6 months 
for inpatient services. These data will then be extrapo-
lated to estimate costs over the time horizon.
Valuation of costs
Once the utilisation of services has been established, we 
will estimate the unit cost of each service. This involves 
sourcing a value for each item (eg, annual cost of 
employment multiplied by proportion of time spent), 
as well as an allocation factor (eg, annual facility head 
count) allowing the estimation of a unit cost (cost of 
employment×proportion of time/headcount). These 
sources of data and allocation factors are outlined in 
detail in table 1.
For capital items, costs will be estimated using the 
replacement value method.37 In essence, the current 
replacement value of each items is calculated and annu-
itized using data on the estimated useful life of the item 
and an interest rate representing the opportunity cost 
component for capital, in order to estimate an equivalent 
annual cost. An estimated useful life of between 5– and 20 
years for furniture and buildings will be applied as while 
an interest rate of 8% will be used as the annuitization 
factor based on the rate of return on government bonds 
in South Africa.37
Estimating costs for the patient perspective
Measurement of resource use
For the patient perspective, we will use a questionnaire at 
baseline, 6 and 12 months to estimate resource use. This 
will capture any user fees associated with public, private 
or NGO-provided health services as well as traditional and 
faith-based therapies. In addition, we will ask patients to 
estimate their time spent accessing healthcare services, as 
well as out-of-pocket payments for transport, subsistence 
and accommodation. Travel, subsistence and accommo-
dation costs will relate to both the patient and their care-
giver, if the patient is accompanied by a caregiver to any 
of these services.
Valuation of costs
Travel, subsistence and accommodation costs will be 
estimated using the out-of-pocket payments reported by 
patients. Time spent receiving healthcare will be valued 
using the equality of wages approach.45 46 We will apply 
this method as public health services in South Africa are 
typically accessed by those who have a lower socioeco-
nomic status. Using this technique, the time costs for all 
patients are valued at the average income reported by the 
survey population.45 This approach is expected to provide 
a relatively accurate reflection of the opportunity cost of 
Cost component
Measurement Valuation
Resources used
Quantities or 
utilisation Valuation data Allocation factor
   Building operating 
and maintenance
Electricity, water, other 
utilities, phone, cleaning, 
transport and stationery
Facility utilisation Facility expenditure Facility headcount
Other related healthcare providers
  Public clinic visit Average cost per visit Patient interviews Facility expenditure Facility headcount
  Public hospital ER/
OPD visit
Average cost per OPD visit Patient interviews Facility expenditure Facility Inpatient 
days and Outpatient 
headcount
  Public hospital 
inpatient day
Average cost per inpatient 
day
Patient interviews Facility expenditure Facility Inpatient 
days and Outpatient 
headcount
Table 1 Continued 
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unpaid labour and is favoured over the minimum wage 
approach in this context as a large proportion of the 
patients are unemployed resulting in a possible overes-
timate of the value of the time loss if the minimum wage 
is used.45 In addition, we will ask patients if they have lost 
any income through seeking healthcare.
Figure 2 summarises the intervention arms, costs and 
outcomes that will be included in this study.
All costs will be valued at 2017/2018 prices and, to allow 
comparability with other studies will be converted from 
South African Rand (ZAR) to US$, using appropriate 
conversion rates for the same period obtained from 
OANDA, an online currency exchange rate conversion 
site. Costs incurred during earlier periods (such as manual 
development) will be inflated using the Consumer Price 
Index to reflect 2017/2018 prices.
Analyses
Statistical analysis of costs and effects
Mean provider costs and patient costs will be calculated 
from baseline until the end of the intervention period. In 
addition, we will explore the extrapolation of costs to later 
periods if data allow for this. Cost differences between the 
MIND-TAU, and the MIND-DES and MIND-DED alterna-
tives will be calculated. Sampling uncertainty for cost data 
will be estimated using statistical methods that account 
for the non-normal distribution of costs. Effect in terms 
of CES-D, AUDIT, HIV viral load, HBA1c and the QALY 
will be analysed using linear regression on intervention 
type.
Determining cost-effectiveness
The analysis will be conducted in line with the Consoli-
dated Health Economic Evaluation Reporting Standards 
guidelines.47 Decision analytical models37 integrating the 
cost and outcomes of the different intervention alterna-
tives will be developed to assess cost-effectiveness. As a 
meaningful impact of the MIND-DES and MIND-DED on 
both costs and effects is anticipated, ICERs will be esti-
mated in terms of incremental cost per natural unit and/
or intermediate outcome for the CEA, and incremental 
cost per QALY gained for the CUA. As the trial is focused 
on health systems strengthening for the delivery of 
mental health services, the decision rule applies to maxi-
mising health within the healthcare budget constraint. 
Therefore, ICERs will be calculated from the provider 
perspective and, the cost per QALY gained will be 
compared with the cost-effectiveness thresholds (CETs) 
for LMIC settings.48 If our intervention's ICER is less than 
the chosen CET, this will mean that diverting resources 
to the intervention will increase population health, and 
if the ICER is more than the CET the intervention is not 
cost-effective. Patient costs will be collected and reported 
on separately. In addition, to satisfy the requirements of 
common guidelines47 and to allow for some degree of 
comparability with other studies, the ICERs will also be 
presented for the societal perspective, that is, including 
both provider and patient costs.
Sensitivity analyses
The decision analytical models will allow for univariate 
and multivariate sensitivity analyses to be conducted. 
This will enable the robustness of study findings to be 
tested by varying key parameters such as utilisation rates 
and assessing the impact on cost-effectiveness results. 
Standard areas of analytical focus will be considered, 
including testing sensitivity around the resource cost 
and prices, and theoretical controversies,49 for example, 
TTO weights50 and discounting of outcomes.36 Further 
Figure 2 Project MIND: intervention arms, costs, outcomes and economic evaluation. HbA1c, haemoglobin A1c; OOP, out-of-
pocket; TAU, treatment as usual.
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analyses to inform the economics of task-sharing will 
include sensitivity analysis focused on economies and 
diseconomies of scale and scope, using detailed data 
from the TMT.51 This will include testing variations in 
staff hours worked, variations in staff mix, lay counsellor 
funding models and infrastructure investments. The 
impact of intervention dosage on outcomes will also be 
assessed in the sensitivity analyses. Statistical methods 
including multiple imputation will be used to manage 
the effect of missing information on costs and effects.52 
These sensitivity analyses are summarised in table 2. 
Probabilistic sensitivity analysis (which allows application 
of CIs to point estimates) will be used for sensitivity anal-
yses of all relevant individual-level variables. The sensi-
tivity analyses will be used to produce a cost-effectiveness 
acceptability curve.
budget impact analysis
There is an increased demand from decision makers in 
both LMIC and HIC settings for estimates of the real 
fiscal implications of investing in health services within 
a defined budget and budgetary period.53 54 Trial-based 
estimates of intervention uptake and population-based 
estimates of numbers in need of the intervention will 
be used in budget impact approximations,55 which 
will be conducted using a mathematical programming 
approach.56 57 Mathematical programming provides a 
useful equity lens for informing policy decisions around 
the provision of care in high burden, high cost contexts.58 
It will involve analysing alternative implementation strate-
gies with differing equity implications subject to a budget 
constraint. This approach aims to support policy making 
by applying principles of constrained maximisation in 
resource allocation.58 The estimates from this study will 
inform policy-level discussions on the fiscal implications 
of investing in primary care mental health services.
EthICs And dIssEMInAtIon
In the CEA we foresee minimal risks to participants, as 
patient level data will be collected through the main trial, 
where, in order to minimise the risk of improper disclosure 
of information study staff will be required to sign a staff 
confidentiality agreement and will be trained and certified 
in protecting human participants. Data collection for the 
trial will be conducted using Computer-Assisted Personal 
Interviewing (CAPI) in which only a unique study identi-
fier is used. Knowledge translation will be through policy 
briefs, and social media as well as peer-reviewed papers, 
and presentations at health economics and mental health 
policy conferences. Engagement with department of 
health policy makers and other key stakeholders will be 
through a policy dialogue workshop linked to the main 
trial’s Stake Holder Advisory Group. Dissemination of 
results to the public will be through press briefings in 
national and local media.
dIsCussIon
The delivery of psychotherapy using varying models of 
task-sharing to less specialised health workers in primary 
care has been shown to be cost-effective in HIC settings 
across a range of mental health conditions59–61 but has 
limited empirical economic evidence in LMICs.51 62 63 This 
study will provide evidence to address this gap. Through 
the CEA, the relative efficiency of each delivery mecha-
nism will be established, enabling a discussion around 
which model produces the best outcomes given the 
available resources. As staff time is expected to be one of 
the main drivers of costs due to the nature of the inter-
vention, we have developed a time tool that will allow 
us to directly measure staff time usage and investigate 
any potential excess capacity (hypothesized to occur 
with the MIND-DED counsellors), and scope economies 
Table 2 Planned sensitivity analyses
Base case Range
Simple sensitivity analysis
  Discount rate 3% 0%–10%
  QALYs: HRQoL weights EQ-5D valued using UK TTO EQ-5D valued using Zimbabwe TTO
  Unit costs Primary data and data from published 
sources and official statistics for South 
Africa
Varied within plausible ranges as 
determined from a literature review of 
South African cost studies
  Missing data Multiple imputation Complete case analysis
Probabilistic sensitivity analysis
  Intervention utilisation data Mean value 95% uncertainty interval
  Referral service utilisation data Mean value 95% uncertainty interval
  EQ-5D/CES-D/AUDIT data Mean value 95% uncertainty interval
  Clinical outcomes (HbA1c, HIV-1 RNA) Mean value 95% uncertainty interval
AUDIT, Alcohol Use Disorder Identification Test; CES-D, Centre for Epidemiological Studies scale on Depression; EQ-5D, EuroQol-5D; HbA1c, 
haemoglobin A1c; HRQoL, health-related quality of life; QALY, quality-adjusted life year; TTO, time trade-off. 
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(hypothesized to occur with the MIND-DES counsel-
lors), which would impact the comparative efficiency of 
the different alternatives and thus the cost-effectiveness 
results, as suggested in a similar study.51 The CUA will aid 
health service planners in their decision making around 
resource allocation and may be useful for guiding priority 
setting decisions both within the mental health budget 
space and across competing health priorities. To further 
support policy maker decisions, the affordability of imple-
menting the intervention will need to be assessed, this 
will require further analysis using trial-based evidence 
on intervention uptake and estimates of population-level 
numbers in need to approximate the budget impact of 
equitably implementing the service.58
Policy discussions on the integration of services to 
provide holistic care for patients requires economic 
evidence to support implementation in resource-limited 
contexts.4 23 By estimating the full economic costs of inte-
grating the mental health treatment into the primary 
care offering for patients with chronic physical diseases, 
this study will provide much needed economic evidence 
to support this policy narrative.4 64 65 Empirical data on 
the costs of upskilling and training staff to deliver the 
intervention and the time costs of the alternative human 
resourcing strategies will also aid in understanding how 
this cadre of staff organise their work and may highlight 
opportunities for efficiency gains. This is timely in the 
current policy window where the idea of a 'facility coun-
sellor' is being discussed, whose role may span a range of 
counselling duties including: adherence counselling for 
TB/HIV, chronic non-communicable physical diseases 
and mental health counselling. The integration of 
services is a key health systems focus66 requiring economic 
evidence.23 The integration of services at the primary care 
level67 to manage communicable and non-communicable 
chronicity is a global challenge20 22 68 69 and a key strategic 
aim of the Department of Health70 for expanding access 
to mental health services and managing chronic diseases 
in South Africa.27 70 Brief interventions for depression and 
alcohol use disorders lack a common outcome measure 
for use in CEA,71 thus limiting comparison across inter-
ventions.72 This study will provide unique cost-effective-
ness evidence using the QALY as an outcome measure 
for such interventions in the South African context.51 
This will allow comparability of cost-effectiveness results73 
and inform value for money decision making.48 74 This 
is of particular importance for South Africa as discus-
sions around cost-effectiveness thresholds74 are being 
increasingly presented in the health policy space in the 
prelude to National Health Insurance. This protocol also 
responds to the call to publish health economics proto-
cols alongside trial protocols to reduce publication bias 
of randomised controlled trial results.75
Potential challenges to this study include recall bias due 
to the reliance on patient-reported health service use for 
our estimations of service utilisation. To limit recall bias, a 
1-month recall period will be used for ambulatory services 
and 6-month recall for hospitalisations.52 Another possible 
limitation is that only a few patients may be referred for 
mental healthcare for CMD in the TAU option so we may 
not fully capture referral costs thus potentially underes-
timating cost-effectiveness. Another potential limitation 
is that the short follow-up period of 12 months may not 
capture the extent of the benefit that patients and the 
health system could gain through the availability of this 
service. For example, the degree to which the socioeco-
nomic benefits and the returns to mental health associ-
ated with such interventions76 may not be fully evident 
by the 12-month end point. This is a common problem 
associated with trial-based economic evaluations.77
FuturE work
Further work associated with this economic evaluation 
includes the use of modelling techniques to estimate the 
long-term benefits of the intervention both at the patient 
and system level and applying cost-benefit techniques to 
strengthen the evidence base for the mental health invest-
ment case.
ConClusIon
Priority setting and decisions around the scale up of an 
integrated comprehensive primary care service need to 
be informed by micro-level and macro-level economic 
analyses of the investment requirements, impact and 
equity implications of delivering key services such as 
counselling. It is anticipated that the cost estimates, the 
CEA and budget impact analysis of this intervention will 
be a useful contribution to priority setting and policy 
making during the current reconfiguration of South Afri-
ca’s health system.78 It is hoped that the economic evalua-
tion of project MIND will provide much needed evidence 
on the cost-effectiveness of integrating mental health 
services into primary care that could support a business 
case for investing in these services.
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